Recent Company News

• 11:03 PM ET Jul 31, 2025
  

  Ono Pharmaceutical reports Q1 net income attributable ¥17.67B vs FactSet ¥24.79B [4 est, ¥23.74-26.50B] (¥1683.0000, -7.5)

• 07:06 AM ET Jul 28, 2025
  

  Ono Pharmaceutical and Deciphera announces positive CHMP opinion for ROMVIMZA (vimseltinib) for treatment of Tenosynovial giant cell Tumor (¥1655.0000, 0)

• 04:49 AM ET Jul 28, 2025
  

  Antengene obtains NMPA approval for XPOVIO combined with bortezomib and dexamethasone for treatment of multiple myeloma (HK$5.53, 0.00)

• 06:41 AM ET Jul 25, 2025
  

  EU's CHMP adopted positive opinion recommending granting of marketing authorisation for Romvimza (¥1630.5000, 0)

• 04:03 AM ET Jun 23, 2025
  

  Ono Pharmaceutical, Vertex Pharmaceuticals to collaborate on povetacicept; terms undisclosed ($440.87, 0.00)

• 08:04 AM ET May 30, 2025
  

  Pfizer reports survival results from Phase 3 BREAKWATER trial of BRAFTOVI combination in mCRC with BRAF V600E mutation ($23.45, 0.00)

• 09:12 AM ET May 28, 2025
  

  Ono Pharmaceutical presents positive results from pivotal phase 2 PROSPECT study of tirabrutinib with relapsed or refractory PCNSL (¥1546.0000, 0)

• 07:01 AM ET May 28, 2025
  

  Bristol Myers Squibb receives European Commission approval for subcutaneous formulation of Opdivo (nivolumab) across multiple solid Tumor indications ($46.89, 0.00)

• 07:03 AM ET May 16, 2025
  

  Bristol Myers Squibb receives EC approval for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by adjuvant Opdivo for resectable NSCLC with PD-L1 expression ≥1% ($45.81, 0.00)

• 12:03 AM ET May 15, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (69 total)